Next step for Xenome
Thursday, 25 September, 2008
Privately held biotech Xenome has begun a Phase II trial of lead candidate Xen2174 for the control of acute post-operative pain.
The trial will enrol approximately 200 patients at multiple clinical sites in the US.
The aim is to evaluate the safety and efficacy of Xen2174 administered as a single intrathecal administration to patients undergoing unilateral bunionectomy, a standard model for the assessment of acute pain therapies.
Xenome is also in Phase II trials of Xen2174 for chronic pain.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
